In situ vaccination by direct dendritic cell inoculation: The coming of age of an old idea?

Research output: Contribution to journalShort surveypeer-review


For more than 25 years, dendritic cell (DC) based vaccination has flashily held promises to represent a therapeutic approach for cancer treatment. While the vast majority of studies has focused on the use of antigen loaded DC, the intratumoral delivery of unloaded DC aiming at in situ vaccination has gained much less attention. Such approach grounds on the ability of inoculated DC to internalize and process antigens directly released by tumor (usually in combination with cell-death-inducing agents) to activate broad patient-specific antitumor T cell response. In this review, we highlight the recent studies in both solid and hematological tumors showing promising clinical results and discuss the main pitfalls and advantages of this approach for endogenous cancer vaccination. Lastly, we discuss how in situ vaccination by DC inoculation may fit with current immunotherapy approaches to expand and prolong patient response.

Original languageEnglish
Article number2303
JournalFrontiers in Immunology
Issue numberSEP
Publication statusPublished - Sep 1 2019


  • Cancer immunotherapy
  • Checkpoint inhibitor combination therapy
  • Dendritic cell (DC)
  • In situ vaccination
  • Intratumor administration
  • Monocyte derived dendritic cells (MoDC)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'In situ vaccination by direct dendritic cell inoculation: The coming of age of an old idea?'. Together they form a unique fingerprint.

Cite this